Innate Pharma SA
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Innate Pharma SA
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
/ 
Frequently asked questions
To buy Innate Pharma SA stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Innate Pharma SA by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Innate Pharma SA is IPH:xpar. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Innate Pharma SA has its primary listing on Euronext Paris. You can trade Innate Pharma SA with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Innate Pharma SA is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include Innate Pharma SA as part of a broader investment portfolio.
Learn more about investing and trading in Saxo's education hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures—so you can make more informed decisions when considering shares like Innate Pharma SA.